USA flag logo/image

An Official Website of the United States Government

RADIORHENIUM ANTIBODIES FOR RADIOIMMUNOTHERAPY

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
3090 		Program Year/Program:
1986 / SBIR
Agency Tracking Number:
3090 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
NEORX CORPORATION
410 W HARRISON ST SEATTLE, WA 98119
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1986
Title: RADIORHENIUM ANTIBODIES FOR RADIOIMMUNOTHERAPY
Agency: HHS
Contract: N/A
Award Amount: $500,000.00
 

Abstract:

THE OBJECTIVE OF THIS PHASE I SBIR PROJECT IS TO DEVELOP A RE-186 AGENT SUITABLE FOR LABELING BIFUNCTIONAL CHELATING AGENT ANTIBODY CONJUGATES. ALTHOUGH CHEMICALLY SIMILAR TO TC-99M, APPLICATION OF RE-186 TO YIELD POTENTIAL THERAPEUTIC RADIOPHARMACEUTICALS PRESENTS PROBLEMS WHICH HAVE YET TO BE SOLVED. SPECIFICALLY, IT IS MUCH MORE DIFFICULT TO MAINTAIN RE IN REDUCED OXIDATION STATES THAN TC, AND THUS RE-LABELED AGENTS HAVE A GREATER TENDENCY TO REVERT TO PERRHENATE. ALSO, LIGAND EXCHANGE REACTIONS ON RE PROCEED MORE SLOWLY THAN DO ANALOGOUS REACTIONS ON TC, AND CONDITIONS USED FOR THE LIGAND EXCHANGE SYNTHESIS OF RE-186 ANTIBODY CONJUGATES WILL HAVE TO BE DEVELOPED TO ALLOW EXCHANGE WHILE PREVENTING LOSS OF REACTIVITY. IN THIS PROJECT WE WILL DEVELOP SEVERAL PROCEDURES NEEDED FOR THE LABELING OF PROTEIN CONJUGATES WITH RE-186. THESE WILL INVOLVE REDUCTION OF PERRHENATE USING AGENTS SUCH AS SN(II), AS WELL AS LIGAND EXCHANGE PROCEDURES USING RE-186 COMPLEXES SUCH AS AND RE-CITRATE. INITIAL EXPERIMENTS WILL BE CONDUCTED WITH THE FREE BIFUNCTIONAL LIGAND, AND SUBSEQUENT EXPERIMENTS WILL UTILIZE THE ANTIBODY CONJUGATES WHICH ARE ALREADY AVAILABLE. LABELING YIELDS WILL BE MONITORED BY HPLC TECHNIQUES. IN VITRO IMMUNOREACTIVITY ASSESSMENT WILL BE DONE TO ASSESS THE EFFECTS OF RADIOLABELING AND CONJUGATION ON ANTIBODIES. THE ABILITY TO LABEL ANTIBODIES WITH RE-186 IS THE FIRST STEP TOWARDS DEVELOPING A RE-186 RADIOIMMUNOTHERAPEUTIC AGENT.

Principal Investigator:

Alan R. Fritzberg
Principal Investigator
2062817001

Business Contact:

Small Business Information at Submission:

Neorx Corp.
410 West Harrison Seattle, WA 98119

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No